Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic peptide: A brief review

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 11, 2004, Pages 791-794

  Woods, Robyn L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atrial natriuretic peptide; B type natriuretic peptide; Cardiac hypertrophy; Cardiomyocytes; Cardioprotective; Diabetes; HS 142 1; Sympathovagal balance; Vagal reflex

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; GLUCOSE; GUANYLATE CYCLASE; HS 142 1; NESIRITIDE; NITRIC OXIDE; RENIN;

BLOOD VOLUME; BRADYCARDIA; CONFERENCE PAPER; DIABETES MELLITUS; DIURESIS; HEART AFTERLOAD; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART PRELOAD; HEART PROTECTION; HUMAN; HYPERTENSION; NONHUMAN; SODIUM EXCRETION; SYMPATHETIC TONE; VAGUS REFLEX;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; CARDIOVASCULAR DISEASES; HEART; HORMONES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE;

EID: 9344227376     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0305-1870.2004.04073.x     Document Type: Conference Paper

References (35)

1. de Bold A, Bruneau B. Kuroski de Buld M. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc. Res. 1996; 31: 7-18.
2. Drewett JG, Garbers DL. The family of guanylyl cyclase receptors and their ligands. Endocr. Rev. 1994; 15: 135-62.
3. Shen Y-T, Young MA, Ohanian J, Graham RM, Vatner SF. Atrial natriuretic factor-induced systemic vasoconstriction in conscious dogs, rats and monkeys. Circ. Res. 1990; 66: 647-61.
4. Woods RL, Anderson WP. Atrial natriuretic peptide infusion causes vasoconstriction after autonomic blockade in conscious dogs. Am. J. Physiol. 1990; 259: R813-22.
5. Woods RL, Smolich JJ. Regional blood flow effects of ANP in conscious dogs: Preferential gastrointestinal vasoconstriction. Am. J. Physiol. 1991; 261: H1961-9.
6. Charles CJ, Espiner EA, Richards AM, Nicholls MG, Yandle TG. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. Am. J. Physiol. 1996; 270: R1324-31.
7. Woods RL, Oliver JR, Korner PI. Direct and neurohumoral cardiovascular effects of atrial natriuretic peptide. J. Cardiovasc. Pharmacol. 1989; 13: 177-85.
8. Woods RL, Jones MJM. Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Am. J. Physiol. 1999; 276: R1443-52.
9. Shen Y-T, Graham RM, Vatner SF. Effects of atrial natriuretic factor on blood flow distribution and vascular resistance in conscious dogs. Am. J. Physiol. 1991; 260: H1893-902.
10. Woods RL. Vasoconstrictor actions of atrial natriuretic peptide in the splanchnic circulation of anesthetized dogs. Am. J. Physiol. 1998; 275: R1822-32.
11. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J. Am. Coll. Cardiol. 2001; 37: 1221-7.
12. Brunner-La Rocca HP, Woods RL, Kaye DM et al. Divergent effects of ANP and BNP in acute heart failure: Evidence for a putative BNP-selective receptor? J. Hypertens. 2002; 20: 1195-201.
13. Maisel AS. Nesiritide. A new therapy for the treatment of heart failure. Cardiovasc. Toxicol. 2003; 3: 37-42.
14. Thomas CJ, Head GA, Woods RL. Similar baroreflex bradycardic actions of atrial natriuretic peptide and B and C types of natriuretic peptides in conscious rats. J. Hypertens. 1999; 17: 801-6.
15. Thomas CJ, May CN, Sharma AD, Woods RL. ANR BNP and CNP enhance bradycardic responses to cardiopulmonary chemoreceptor activation in conscious sheep. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001; 280: R282-8.
16. Thomas CJ, Rankin AJ, Head GA, Woods RL. ANP enhances bradycardic reflexes in normotensive but not spontaneously hypertensive rats. Hypertension 1997; 29: 1126-32.
17. Thomas CJ, Head GA, Woods RL. ANP and bradycardic reflexes in hypertensive rats: Influence of cardiac hypertrophy. Hypertension 1998; 32: 548-55.
18. Thomas CJ, Allen AM, McAllen RM, Woods RL. ANP potentiates nonarterial baroreflex bradycardia: Evidence from sinoaortic denervation in rats. Auton. Neurosci. 2002; 97: 89-98.
19. Thomas CJ, Woods RL. Guanylyl-cyclase receptors mediate cardiopulmonary vagal reflex actions of ANP. Hypertension 2003; 41: 279-85.
20. Woods RL, Courneya CA, Head GA. Nonuniform enhancement of baroreflex sensitivity by atrial natriuretic peptide in conscious rats and dogs. Am. J. Physiol. 1994; 267: R678-86.
21. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992; 86: 1081-8.
22. Koller KJ, Lowe DG, Bennett GL et al. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science 1991; 252: 120-3.
23. Espiner EA, Richards MR, Yandle TG, Nicholls MG. Natriuretic hormones. Endocrinol. Metab. Clin. 1995; 24: 481-509.
24. Deliva RD, Ackermann U. Atrial natriuretic peptide and mechanisms of cardiovascular control. Role of serotonergic receptors. Am. J. Physiol. 1998; 274: R711-17.
25. Vanoli E, deFerrair GM, Stramba-Badiale M, Hull SS, Foreman RD, Schwanz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ. Res. 1991; 68: 1471-81.
26. Esler MD. Sympathetic nervous system: Contribution to human hypertension and related cardiovascular diseases. J. Cardiovasc. Pharmacol. 1995; 26 (Suppl. 2): S24-8.
27. Thoren P, Mark AL, Morgan DA, O'Neill TP, Needleman P, Brody MJ. Activation of vagal depressor reflexes by atriopeptin inhibits renal sympathetic nerve activity. Am. J. Physiol. 1986; 251: H1252-9.
28. Floras JS. Sympathoinhibitory effects of atrial natriuretic factor in normal humans. Circulation 1990; 81: 1860-73.
29. Oliver PM. Fox JE, Kim R et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl Acad. Sci. USA 1997; 94: 14 730-5.
30. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest. 1998; 101: 812-18.
31. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35: 19-24.
32. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: Importance of cyclic GMP. Cardiovasc. Res. 2003; 57: 515-22.
33. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH. B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: Importance of cyclic GMP. Diabetes 2003; 52: 2389-95.
34. Holtwick R, van Eickels M, Skryabin BV et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Invest. 2003; 111: 1399-407.
35. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J. Card. Fail. 2001; 7: 92-100.